MYC activity is negatively regulated by a C-terminal lysine cluster

Oncogene

Volumn 33, Issue 8, 2014, Pages 1066-1072

  Wasylishen, A R ^a,b   Kalkat, M ^a,b   Kim, S S ^a,b   Pandyra, A ^a,b   Chan, P K ^b   Oliveri, S ^a,b   Sedivy, E ^a,b   Konforte, D ^b   Bros, C ^b   Raught, B ^a,b   Penn, L Z ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Apoptosis; Cellular transformation; Lysine; Myc; Transcription

Indexed keywords

ANIMALS; CELL DIVISION; GENE EXPRESSION REGULATION; GENES, MYC; HETEROGRAFTS; HUMANS; LYSINE; NEOPLASMS; PHOSPHORYLATION; PROTEIN STABILITY; RATS;

EID: 84894535205     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.36     Document Type: Article

References (28)

1. Hann SR. Role of post-Translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol 2006; 16: 288-302
2. Sears RC. The life cycle of C-myc: From synthesis to degradation. Cell Cycle 2004; 3: 1133-1137
3. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007; 9: 765-774
4. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5: 56-61
5. Rabbitts TH, Hamlyn PH, Baer R. Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 1984; 306: 760-765
6. Chang DW, Claassen GF, Hann SR, Cole MD. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol 2000; 20: 4309-4319
7. Thibodeaux CA, Liu X, Disbrow GL, Zhang Y, Rone JD, Haddad BR et al. Immortalization and transformation of human mammary epithelial cells by a tumor-derived Myc mutant. Breast Cancer Res Treat 2009; 116: 281-294
8. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 2011; 71: 925-936
9. Conzen SD, Gottlob K, Kandel ES, Khanduri P, Wagner AJ, O'Leary M et al. Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: Transrepression correlates with acceleration of apoptosis. Mol Cell Biol 2000; 20: 6008-6018
10. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005; 436: 807-811
11. Adhikary S, Marinoni F, Hock A, Hulleman E, Popov N, Beier R et al. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 2005; 123: 409-421
12. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 2011; 44: 325-340
13. Patel JH, Du Y, Ard PG, Phillips C, Carella B, Chen CJ et al. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 2004; 24: 10826-10834
14. Zhang K, Faiola F, Martinez E. Six lysine residues on c-Myc are direct substrates for acetylation by p300. Biochem Biophys Res Commun 2005; 336: 274-280
15. Wasylishen AR, Stojanova A, Oliveri S, Rust AC, Schimmer AD, Penn LZ. New model systems provide insights into Myc-induced transformation. Oncogene 2011; 30: 3727-3734
16. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997; 8: 1039-1048
17. Faiola F, Liu X, Lo S, Pan S, Zhang K, Lymar E et al. Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription. Mol Cell Biol 2005; 25: 10220-10234
18. Berns K, Hijmans EM, Koh E, Daley GQ, Bernards R. A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts. Oncogene 2000; 19: 3330-3334
19. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151: 56-67
20. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012; 151: 68-79
21. Callus BA, Ekert PG, Heraud JE, Jabbour AM, Kotevski A, Vince JE et al. Cytoplasmic p53 is not required for PUMA-induced apoptosis. Cell Death Differ 2008; 15: 213-215author reply 5-6
22. Stone J, de Lange T, Ramsay G, Jakobovits E, Bishop JM, Varmus H et al. Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol Cell Biol 1987; 7: 1697-1709
23. Graves JA, Rothermund K, Wang T, Qian W, Van Houten B, Prochownik EV. Point mutations in c-Myc uncouple neoplastic transformation from multiple other phenotypes in rat fibroblasts. PLoS One 5: E13717
24. Ngo CV, Gee M, Akhtar N, Yu D, Volpert O, Auerbach R et al. An in vivo function for the transforming Myc protein: Elicitation of the angiogenic phenotype. Cell Growth Differ 2000; 11: 201-210
25. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 2001; 98: 4510-4515
26. Marhin WW, Chen S, Facchini LM, Fornace Jr AJ, Penn LZ. Myc represses the growth arrest gene gadd45. Oncogene 1997; 14: 2825-2834
27. Oster SK, Mao DY, Kennedy J, Penn LZ. Functional analysis of the N-Terminal domain of the Myc oncoprotein. Oncogene 2003; 22: 1998-2010
28. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268.